keyword
MENU ▼
Read by QxMD icon Read
search

Deauville lymphoma

keyword
https://www.readbyqxmd.com/read/28798034/fdg-pet-ct-in-lymphoma-has-imaging-directed-personalized-medicine-become-a-reality
#1
Sally F Barrington, Peter Wm Johnson
Positron emission tomography with computed tomography (PET-CT) using (18)F- fluorodeoxyglucose (FDG) is an essential part of the management of patients with lymphoma. Efforts to standardize PET acquisition and reporting, including the five-point 'Deauville scale', have enabled PET to become a surrogate for treatment success/failure in common lymphoma subtypes. This review summarizes the key evidence from clinical trials that supports PET-directed personalized approaches in lymphoma. PET-guided therapy has improved outcomes in Hodgkin lymphoma, using less chemotherapy and more selective radiotherapy...
August 10, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/28750493/concomitant-semi-quantitative-and-visual-analysis-improves-the-predictive-value-on-treatment-outcome-of-interim-18f-fluorodeoxyglucose-positron-emission-tomography-in-advanced-hodgkin-lymphoma
#2
Alberto Biggi, Fabrizio Bergesio, Stephane Chauvie, Andrea Bianchi, Massimo Menga, Federico Fallanca, Martin Hutchings, Michele Gregianin, Michel Meignan, Andrea Gallamini
BACKGROUND: Qualitative assessment using the Deauville five-point scale (DS) is the gold standard for interim and end-of treatment PET interpretation in lymphoma. In the present study we assessed the reliability and the prognostic value of different semi- quantitative (SQ) parameters in comparison with DS for interim PET (iPET) interpretation in Hodgkin lymphoma (HL). METHODS: A cohort of 82 out of 260 patients with advanced stage HL enrolled in the International Validation Study (IVS), scored as 3 to 5 by the expert panel was included in the present report...
July 27, 2017: Quarterly Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28741053/prediction-of-outcome-in-pediatric-hodgkin-lymphoma-based-on-interpretation-of-18-fdg-pet-ct-according-to-%C3%AE-suvmax-deauville-5-point-scale-and-ihp-criteria
#3
Emine Göknur Isik, Serkan Kuyumcu, Rejin Kebudi, Yasemin Sanli, Zeynep Karakas, Fatma Betul Cakir, Seher Nilgün Unal
OBJECTIVE: Minimizing side effects by using response-adopted therapy strategies plays an important role in the management of pediatric Hodgkin lymphoma (HL); however, the criteria for the definition of adequate or inadequate response are controversial. The aim of this study is to compare different methods of interpretation of (18)F-FDG-PET/CT (PET) in the prediction of disease outcome in order to determine the optimum method in this regard. METHODS: Baseline, interim and post-treatment PET scans of 72 children were interpreted according to revised International Harmonization Project criteria (IHP) and Deauville criteria...
July 24, 2017: Annals of Nuclear Medicine
https://www.readbyqxmd.com/read/28733763/predictive-value-of-18-f-fdg-pet-ct-in-adults-with-t-cell-lymphoblastic-lymphoma-post-hoc-analysis-of-results-from-the-graall-lysa-llo3-trial
#4
Stéphanie Becker, Thomas Vermeulin, Anne-Ségolène Cottereau, Nicolas Boissel, Pierre Vera, Stéphane Lepretre
PURPOSE: We examined whether FDG PET can be used to predict outcome in patients with lymphoblastic lymphoma (LL). METHODS: This was a retrospective post hoc analysis of data from the GRAAL-LYSA LL03 trial, in which the treatment of LL using an adapted paediatric-like acute lymphoblastic leukaemia protocol was evaluated. PET data acquired at baseline and after induction were analysed. Maximum standardized uptake values (SUVmax), total metabolic tumour volume and total lesion glycolysis were measured at baseline...
July 21, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28696028/pretransplant-functional-imaging-and-outcome-in-pediatric-patients-with-relapsed-refractory-hodgkin-lymphoma-undergoing-autologous-transplantation
#5
Nmazuo W Ozuah, Hisham M Dahmoush, Frederick D Grant, Leslie E Lehmann, Ann S LaCasce, Amy L Billett, Steven P Margossian
BACKGROUND: Pretransplant functional imaging (FI), particularly a negative positron emission tomography (PET), is a strong predictor of outcome in adults with relapsed or refractory Hodgkin lymphoma (HL), but data in pediatrics are limited. METHODS: The medical records of 49 consecutive pediatric patients, who received autologous transplant at a single institution, were retrospectively analyzed. All patients had either gallium or PET scan before transplant and were conditioned with carmustine, etoposide, cytarabine, and melphalan (BEAM)...
July 11, 2017: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/28692029/pre-autologous-transplantation-pet-ct-using-deauville-criteria-is-an-independent-predictor-of-progression-in-relapsed-refractory-classical-hodgkin-lymphoma
#6
M Damlaj, S Ghazi, G Syed, T Pasha, G Gmati, H Salama, O Ali, K A Abuelgasim, M Al-Zahrani, A Hejazi, A Al Askar
No abstract text is available yet for this article.
July 10, 2017: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/28686510/somatostatin-receptor-expression-in-lymphomas-a-source-of-false-diagnosis-of-neuroendocrine-tumor-at-68-ga-dotanoc-pet-ct-imaging
#7
Tiina Ruuska, Yadith Ramírez Escalante, Samuli Vaittinen, Maria Gardberg, Aida Kiviniemi, Päivi Marjamäki, Jukka Kemppainen, Sirkku Jyrkkiö, Heikki Minn
BACKGROUND: (68)Ga-DOTANOC PET/CT is routinely used to image neuroendocrine tumors (NETs). A case of lymphoma initially thought to be NET based on a positive (68)Ga-DOTANOC PET/CT was recently seen at our institution. This prompted us to determine prospectively somatostatin receptor (SSTR) status in patients with lymphoma by immunohistochemical analysis of SSTR subtypes 2, 3 and 5 (SSTR2,3,5) and (68)Ga-DOTANOC PET/CT imaging. MATERIAL AND METHODS: Twenty-one patients with newly diagnosed lymphoma were referred to (68)Ga-DOTANOC and FDG PET/CT prior to any treatment...
July 7, 2017: Acta Oncologica
https://www.readbyqxmd.com/read/28660348/the-role-of-f-18-fdg-pet-ct-in-evaluating-the-impact-of-hiv-infection-on-tumor-burden-and-therapy-outcome-in-patients-with-hodgkin-lymphoma
#8
Ismaheel O Lawal, Nozipho E Nyakale, Lerwine M Harry, Moshe R Modiselle, Alfred O Ankrah, Alphonse P Msomi, Neo P Mokgoro, Tebatso G Boshomane, Christophe Van de Wiele, Mike M Sathekge
BACKGROUND: To evaluate the impact of HIV infection on tumor burden and therapy outcome following treatment with chemotherapy in patients with Hodgkin lymphoma. METHODS: A total of 136 patients with classical Hodgkin lymphoma were studied (mean age ± SD = 32.31 ± 1.39 years, male = 86, female = 50). Advanced disease (stage III and IV) was present in 64% of patients. HIV infection was present in 57 patients while 79 patients were HIV-negative. Baseline F-18 FDG PET/CT was obtained in all patients...
June 28, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28634685/poor-predictive-value-of-positive-interim-fdg-pet-ct-in-primary-mediastinal-large-b-cell-lymphoma
#9
Julien Lazarovici, Marie Terroir, Julia Arfi-Rouche, Jean-Marie Michot, Sacha Mussot, Valentina Florea, Maria-Rosa Ghigna, Peggy Dartigues, Cynthia Petrovanu, Alina Danu, Christophe Fermé, Vincent Ribrag, David Ghez
PURPOSE: Though commonly used to assess response to therapy, the prognostic value of interim FDG-PET/CT in Primary Mediastinal Large B-cell Lymphoma (PMBCL) is unclear. METHODS: We conducted a retrospective study on 36 consecutive patients treated at our institution for a PMBCL between 2006 and 2014. All patients with a positive interim FDG-PET/CT had undergone histological restaging consisting either in a surgical debulking of the residual lesion (15 patients) or a CT-guided core needle biopsy (two patients)...
June 21, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28629257/risk-stratification-of-diffuse-large-b-cell-lymphoma-with-interim-pet-ct-based-on-different-cutoff-deauville-scores
#10
Jihyun Kim, Yoo Sung Song, Jong Seok Lee, Won Woo Lee, Sang Eun Kim
We evaluated the usefulness of interim (18)F-FDG PET/CT for risk stratification using different cutoff values of the Deauville 5-point scale (5-DS) in DLBCL patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). One hundred and fifty patients underwent interim (I-) and end of treatment (EOT-) PET/CT scans. Applying the conventional 5-DS cutoff value of scores 4 to 5 at interim, there was no significant difference in progression free survival (PFS) between I-PET negative and I-PET positive patients...
June 20, 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/28535082/evaluating-early-interim-fluorine-18-fluorodeoxyglucose-positron-emission-tomography-computed-tomography-with-the-suvmax-liver-based-interpretation-for-predicting-the-outcome-in-diffuse-large-b-cell-lymphoma
#11
Yang Fan, Yuewei Zhang, Zhi Yang, Zhitao Ying, Nina Zhou, Chen Liu, Yuqin Song, Jun Zhu, Xuejuan Wang
Interim (18)F-FDG PET/CT is an effective predictor in patients with DLBCL, but the standard evaluating criteria were controversial. In this study, investigators tried to investigate whether the liver SUVmax (SUVmax-liver)-based interpretation could improve the accuracy of predicting the outcomes, comparing with the Deauville five-point scale (5-PS) and the reduction rate of the maximum standardized uptake value (ΔSUVmax) criteria. In 119 patients, PET/CT after two chemotherapy cycles (PET2) were evaluated with the SUVmax-liver-based interpretation, 5-PS, and ΔSUVmax criteria...
September 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/28513853/association-between-textural-and-morphological-tumor-indices-on-baseline-pet-ct-and-early-metabolic-response-on-interim-pet-ct-in-bulky-malignant-lymphomas
#12
Fayçal Ben Bouallègue, Yassine Al Tabaa, Marilyne Kafrouni, Guillaume Cartron, Fabien Vauchot, Denis Mariano-Goulart
PURPOSE: We investigated whether metabolic, textural and morphological tumoral indices evaluated on baseline PET-CT were predictive of early metabolic response on interim PET-CT in a cohort of patients with bulky Hodgkin and non-Hodgkin malignant lymphomas. METHODS: This retrospective study included 57 patients referred for initial PET-CT examination. In-house dedicated software was used to delineate tumor contours using a fixed 30% threshold of SUV max and then to compute tumoral metabolic parameters (SUV max, mean, peak, standard deviation, skewness and kurtosis, metabolic tumoral volume (MTV), total lesion glycolysis, and area under the curve of the cumulative histogram), textural parameters (Moran's and Geary's indices, energy, entropy, contrast, correlation derived from the gray-level co-occurrence matrix, area under the curve of the power spectral density, auto-correlation distance, and granularity), and shape parameters (surface, asphericity, convexity, surfacic extension, and 2D and 3D fractal dimensions)...
May 17, 2017: Medical Physics
https://www.readbyqxmd.com/read/28498337/imaging-of-early-response-to-predict-prognosis-in-the-first-line-management-of-follicular-non-hodgkin-lymphoma-with-iodine-131-rituximab-radioimmunotherapy
#13
Murali Kesavan, Jan Boucek, William MacDonald, Andrew McQuillan, J Harvey Turner
The purpose of this study was to evaluate prediction of prognosis after first-line radioimmunotherapy (RIT) of advanced follicular non-Hodgkin lymphoma (FL), by imaging with fluorine-18-fluorodeoxyglucose positron emission tomography with computed tomography ((18)F-FDG-PET/CT) three months after induction treatment by Iodine-131-rituximab ((131)I-rituximab). Objective response was determined using the Deauville 5-point scale in 68 prospective clinical trial patients. Baseline (18)F-FDG-PET/CT studies were used to calculate total-metabolic-tumor-volume (TMTV)...
May 12, 2017: Diagnostics
https://www.readbyqxmd.com/read/28485042/prognostic-models-for-primary-mediastinal-thymic-b-cell-lymphoma-derived-from-18-fdg-pet-ct-quantitative-parameters-in-the-international-extranodal-lymphoma-study-group-ielsg-26-study
#14
Luca Ceriani, Maurizio Martelli, Annarita Conconi, Pier L Zinzani, Andrés J M Ferreri, Barbara Botto, Caterina Stelitano, Manuel Gotti, Maria G Cabras, Luigi Rigacci, Luca Giovanella, Emanuele Zucca, Peter W M Johnson
The International Extranodal Lymphoma Study Group-26 study evaluated the prognostic role of 18-fluorodeoxyglucose positron-emission tomography (PET) in primary mediastinal large B-cell lymphoma. We assessed quantitative PET parameters at diagnosis and post-treatment in 100 patients. The end-of-therapy total lesion glycolysis (TLG) was the best individual outcome predictor, but the combination of baseline TLG and end-of-therapy visual analysis with Deauville Score (DS) showed a better positive predictive value...
May 9, 2017: British Journal of Haematology
https://www.readbyqxmd.com/read/28483374/-18-f-fdg-pet-ct-in-the-clinical-management-of-patients-with-lymphoma
#15
P Tamayo, A Martín, L Díaz, M Cabrero, R García, P García-Talavera, D Caballero
The aim of this work was to review the current recommendations for staging and response assessment of patients with Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) in routine clinical practice after chemotherapy and/or stem cell transplantation. A five-point scale (5-PS) from the First International Workshop on PET in Lymphoma in Deauville, France, in 2009, was recommended as the standard tool to score imaging to assess treatment response in patients with lymphoma using (18)F-Fluorodeoxyglucose (FDG) PET/CT...
May 5, 2017: Revista Española de Medicina Nuclear e Imagen Molecular
https://www.readbyqxmd.com/read/28483373/optimisation-of-metabolic-criteria-in-the-prognostic-assessment-in-patients-with-lymphoma-a-multicentre-study
#16
M Del Puig Cózar-Santiago, J R García-Garzón, M Moragas-Freixa, M Soler-Peter, P Bassa Massanas, M Sánchez-Delgado, R Sanchez-Jurado, J E Aguilar-Barrios, R Sanz-Llorens, J Ferrer-Rebolleda
OBJECTIVE: To compare sensitivity, specificity and predictive value of Deauville score (DS) vs. ΔSUVmax in interim-treatment PET (iPET) and end-treatment PET (ePET), in patients with diffuse large B cell lymphoma (DLBCL), Hodgkin lymphoma (HL), and follicular lymphoma (FL). METHOD: Retrospective longitudinal multicentre study including 138 patients (46 DLBCL, 46 HL, 46 FL), on whom 3 (18)F-FDG PET/CT were performed: baseline, iPET, and ePET. Visual (DS) and semi-quantitative (ΔSUVmax) parameters were determined for iPET and ePET...
May 5, 2017: Revista Española de Medicina Nuclear e Imagen Molecular
https://www.readbyqxmd.com/read/28476741/hodgkin-lymphoma-version-1-2017-nccn-clinical-practice-guidelines-in-oncology
#17
Richard T Hoppe, Ranjana H Advani, Weiyun Z Ai, Richard F Ambinder, Patricia Aoun, Celeste M Bello, Cecil M Benitez, Karl Bernat, Philip J Bierman, Kristie A Blum, Robert Chen, Bouthaina Dabaja, Andres Forero, Leo I Gordon, Francisco J Hernandez-Ilizaliturri, Ephraim P Hochberg, Jiayi Huang, Patrick B Johnston, Mark S Kaminski, Vaishalee P Kenkre, Nadia Khan, David G Maloney, Peter M Mauch, Monika Metzger, Joseph O Moore, David Morgan, Craig H Moskowitz, Carolyn Mulroney, Matthew Poppe, Rachel Rabinovitch, Stuart Seropian, Mitchell Smith, Jane N Winter, Joachim Yahalom, Jennifer Burns, Ndiya Ogba, Hema Sundar
This portion of the NCCN Guidelines for Hodgkin lymphoma (HL) focuses on the management of classical HL. Current management of classical HL involves initial treatment with chemotherapy or combined modality therapy followed by restaging with PET/CT to assess treatment response using the Deauville criteria (5-point scale). The introduction of less toxic and more effective regimens has significantly advanced HL cure rates. However, long-term follow-up after completion of treatment is essential to determine potential long-term effects...
May 2017: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/28411336/fdg-pet-for-therapy-monitoring-in-hodgkin-and-non-hodgkin-lymphomas
#18
REVIEW
Sally F Barrington, Regine Kluge
PET using (18)F-FDG for treatment monitoring in patients with lymphoma is one of the most well-developed clinical applications. PET/CT is nowadays used during treatment to assess chemosensitivity, with response-adapted therapy given according to 'interim' PET in clinical practice to adults and children with Hodgkin lymphoma. PET is also used to assess remission from disease and to predict prognosis in the pretransplant setting. Mature data have been reported for the common subtypes of aggressive B-cell lymphomas, with more recent data also supporting the use of PET for response assessment in T-cell lymphomas...
April 14, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28264597/report-of-the-6th-international-workshop-on-pet-in-lymphoma
#19
Cristina Nanni, Anne Ségolène Cottereau, Egesta Lopci, Caroline Bodet-Milin, Monica Coronado, Barbara Pro, Wong Seog Kim, Judith Trotman, Sally Barrington, Ulrich Duhrsen, Thierry Vander Borght, Elena Zamagni, Françoise Kraeber-Bodéré, Christina Messiou, Alain Rahmouni, Irène Buvat, Marc Andre, Mark Hertzberg, Wim Oyen, Olivier Casasnovas, Stefano Luminari, Laurent Garderet, Françoise Montravers, Carsten Kobe, Regine Kluge, Annibale Versari, Emanuele Zucca, Philippe Moreau, Bruce Cheson, Corinne Haioun, Andrea Gallamini, Michel Meignan
Two hundred and ten nuclear medicine physicians, radiologists, and hematologists from 26 countries attended the 6th International Workshop on Positron Emission Tomography (PET) in Lymphoma and Myeloma held in Menton, France, in September 2016. The meeting was under the auspices of the European Lymphoma Institute (ELI), the European Association of Nuclear Medicine (EANM) the Lymphoma Study Association (LYSA), the Italian Foundation on Lymphoma (FIL) and the Carnot Institute for Lymphoma (CALYM). Forty scientific posters were presented...
March 7, 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/28236583/progression-free-survival-of-early-interim-pet-positive-patients-with-advanced-stage-hodgkin-s-lymphoma-treated-with-beacoppescalated-alone-or-in-combination-with-rituximab-hd18-an-open-label-international-randomised-phase-3-study-by-the-german-hodgkin-study
#20
RANDOMIZED CONTROLLED TRIAL
Peter Borchmann, Heinz Haverkamp, Andreas Lohri, Ulrich Mey, Stefanie Kreissl, Richard Greil, Jana Markova, Michaela Feuring-Buske, Julia Meissner, Ulrich Dührsen, Helmut Ostermann, Ulrich Keller, Georg Maschmeyer, Georg Kuhnert, Markus Dietlein, Carsten Kobe, Hans Eich, Christian Baues, Harald Stein, Michael Fuchs, Volker Diehl, Andreas Engert
BACKGROUND: Advanced stage Hodgkin's lymphoma represents a heterogeneous group of patients with different risk profiles. Data suggests that interim PET assessment during chemotherapy is superior to baseline international prognostic scoring in terms of predicting long-term treatment outcome in patients with Hodgkin's lymphoma. We therefore hypothesised that early interim PET-imaging after two courses of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP) might be suitable for guiding treatment in patients with advanced stage Hodgkin's lymphoma...
April 2017: Lancet Oncology
keyword
keyword
91274
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"